• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Figure 3. Cost-effectiveness probability plane as a function of the initial sulfadoxine-pyrimethamine (SP) level of resistance and the ratio of growth rate of artemisinin-based combination therapy (ACT) resistance relative to the growth rate of SP (r ACT /r SP ).

Figure 3

Cost-effectiveness probability plane as a function of the initial sulfadoxine-pyrimethamine (SP) level of resistance and the ratio of growth rate of artemisinin-based combination therapy (ACT) resistance relative to the growth rate of SP (r ACT /r SP ). The lighter area represents 95% of model iterations returning an incremental cost effectiveness ratio (ICER) < $150/disability adjusted life years (DALYs) averted. The darker area represents the probability that the ICER is < $150/DALYs averted is less than 95%. The border of the lighter and darker areas represents the critical rate at which ACT resistance must develop, relative to SP, to be 95% certain that the introduction of the ACT will be cost-effective. The results were obtained using the variables described in Table 1 and assuming an ACT starting resistance of 0.001, an annual discount rate of 3%, and a time frame of (a) five years, (b) 10 years, and (c) 15 years.

From: A Threshold Analysis of the Cost-Effectiveness of Artemisinin-based Combination Therapies in Sub-Saharan Africa

Cover of The Intolerable Burden of Malaria II: What's New, What's Needed
The Intolerable Burden of Malaria II: What's New, What's Needed: Supplement to Volume 71(2) of the American Journal of Tropical Medicine and Hygiene.
Breman JG, Alilio MS, Mills A, editors.
Copyright © 2004, American Society of Tropical Medicine and Hygiene.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.